JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2017, 66(5):233-237 | DOI: 10.36290/csf.2017.034

Idiopathic thrombocytopenia refractery to therapy of cyclosporine A in clinical practice - case report

Lucia Schwarzová1, Zdenko Pirník1,2,*, Natália Štecová3
1 Ústav humánnej a klinickej farmakológie, Katedra farmakológie a toxikológie, Univerzita veterinárskeho lekárstva a farmácie, Košice, SR
2 Ústav experimentálnej endokrinológie BMC SAV
3 Klinika hematológie a onkohematológie, Univerzitná nemocnica Louisa Pasteura, Košice, SR

Primary immune thrombocytopenia (idiopathic thrombocytopenic purpura; ITP) is an autoimmune disorder characterized by isolated thrombocytopenia without abnormalities in the erythroid and myeloid/lymphoid lineages. The incidence of ITP in adults is estimated at approximately 1.6-3.9 per 100 000 persons/year. The aim of this study was to analyze a case report of a patient with diagnosed immune thrombocytopenia (D69.3) resistant to cyclosporine A therapy as well as an evaluation of factors that could contribute to an inadequate response to cyclosporine A. The results show a multifactorial origin of thrombocytopenia and a possible effect on refractivity to cyclosporine A therapy caused by long-term smoking, MDR-1 gene polymorphism, genetic predisposition to autoimmune diseases, allergic reactions as a manifestation of hypersensitivity in the immune system, controversial compliance of the patient, overcome infections as well as impact of drugs taken.

Keywords: immune thrombocytopenia; refractery form; cyclosporine A; therapy; platelets

Received: July 2, 2017; Accepted: October 2, 2017; Published: May 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Schwarzová L, Pirník Z, Štecová N. Idiopathic thrombocytopenia refractery to therapy of cyclosporine A in clinical practice - case report. Čes. slov. farm. 2017;66(5):233-237. doi: 10.36290/csf.2017.034.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Lakshmanan S., Cuker A. Contemporary management of primary immune thrombocytopenia in adults. Journal of Thrombosis and Haemostasis 2012; 10, 1988-1998. Go to original source... Go to PubMed...
    2. Cines D. B., et al. The Handbook First Edition. Immune thrombocytopenia. European School of Haematology 2011.
    3. Penka M., a kol. Neonkologická hematologie. Praha: Grada Publishing 2009.
    4. Mizutani H., et al. Mechanisms of corticosteroid action in immune thrombocytopenic purpura (ITP): experimental studies using ITP-prone mice. Blood 1992; 79, 942-947. Go to original source...
    5. Kahan B. D. Cyclosporine. The New England Journal of Medicine 1989; 321, 1725-1738. Go to original source... Go to PubMed...
    6. Emilia G., et al. Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura. Blood 2002; 99, 1482-1485. Go to original source... Go to PubMed...
    7. Vyse T. J., Todd J. A. Genetic analysis of autoimmune disease. Cell 1996; 85, 311-318. Go to original source... Go to PubMed...
    8. Shiozaki H., et al. Autoantibodies neutralizing thrombopoietin in a patient with amegakaryocytic thrombocytopenic purpura. Blood 2000; 95, 2187-2188. Go to original source...
    9. Gesundheit B., et al. Cyclosporin A in the treatment of refractory immune thrombocytopenic purpura in children. European Journal of Haematology 2001; 66, 347-351. Go to original source... Go to PubMed...
    10. Neylon A. J., et al. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patient. British Journal of Haematology 2003; 122, 966-974. Go to original source... Go to PubMed...
    11. Simanek R., et al. Late spontaneous remissions in severe adult autoimmune thrombocytopenia. Annals of Hematology 2007; 86, 705-710. Go to original source... Go to PubMed...
    12. Khawandanah M. O., et al. Autoimmune hemolytic anemia and thrombocytopenia attributed to an intrauterine contraceptive device. Transfusion 2015; 55, 657-660. Go to original source... Go to PubMed...
    13. Súhrn charakteristických vlastností lieku. Equoral 100 mg. Štátny ústav pre kontrolu liečiv. Dostupné z: https://www.adcc.sk/web/humanne-lieky/spc/equoral-100-mg-spc-6549.html
    14. Súhrn charakteristických vlastností lieku. Sandimmun Neoral. 100mg. Státní ústav pro kontrolu léčiv. http://www.sukl.cz/modules/medication/detail.php?code=0015641&tab=texts
    15. Tesfaye H., et al. Cyclosporine use in miscellaneous clinical settings other than organ transplantations: Is there any evidence for target levels? Annals of Transplantation 2008; 13, 34-40.
    16. Choi P. Y., et al. A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4). Blood 2015; 126, 500-503. Go to original source... Go to PubMed...
    17. Pasquale D., et al. Chronic relapsing thrombotic thrombocytopenic purpura: role of therapy with cyclosporine. American Journal of Hematology 1998; 57, 57-61. Go to original source...
    18. Souček M., a kol. Vnitřní lékařství. 1. díl. Praha: Grada Publishing 2011.
    19. Provan, D., Newland A. C. Current Management of Primary Immune Thrombocytopenia. Advances in therapy 2015; 32, 875-887. Go to original source... Go to PubMed...
    20. Choudhary D. R., et al. Efficacy of cyclosporine as a single agent therapy in chronic idiopathic thrombocytopenic purpura. Haematologica 2008; 93, e61. Go to original source... Go to PubMed...
    21. Daniel F., et al. Multidrug Resistance Gene-1 Polymorphisms and Resistance to Cyclosporine A in Patients with Steroid Resistant Ulcerative Colitis. Inflammatory Bowel Disease 2007; 13, 19-23. Go to original source... Go to PubMed...
    22. Sipeky C., et al. Genetic variability and haplotype profile of MDR1 (ABCB1) in Roma and Hungarian population samples with a review of the literature. Drug metabolism and Pharmacokinetics 2011; 26, 206-215. Go to original source... Go to PubMed...
    23. Abrams C.S., et al. Thrombocytopenia. Goldman's Cecil Medicine. 25th ed. Philadelphia, PA: Elsevier Saunders 2016.
    24. Agarwal A., et al. Fluconazole-induced thrombocytopenia. Annals of Internal Medicine 1990; 113, 899. Go to original source... Go to PubMed...
    25. Bemt V. D., et al. Drug-induced immune thrombocytopenia. Drug Safety 2004; 27, 1243-1252. Go to original source... Go to PubMed...
    26. Buck M. L. Drug-induced Thrombocytopenia. Pediatric Cases from the Medical Literature. Pediatric Pharmacology 2010; 16, 1-4.
    27. Visentin G. P., Liu C. Y. Drug induced Thrombocytopenia. Hematology/Oncology Clinics of North America 2007; 21, 685-693. Go to original source... Go to PubMed...
    28. Bangia A. V., et al. Ranitidine-induced thrombocytopenia: A rare drug reaction. Indian Journal of Pharmacology 2011; 43, 76-77. Go to original source... Go to PubMed...
    29. Royer B., et al. Methylprednisolone-induced immune thrombocytopenia. Blood 2010; 115, 5431-5432. Go to original source... Go to PubMed...
    30. Ahmed I., et al. Heparin induced thrombocytopenia: diagnosis and management update. Postgraduate Medical Journal 2007; 83, 575-582. Go to original source... Go to PubMed...
    31. Reese J. A., et al. Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. Blood 2010; 116, 2127-2133. Go to original source... Go to PubMed...
    32. Grosbois B., et al. Thrombocytopenia induced by angiotensin converting enzyme inhibitors. British Journal of Medicine 1989; 298, 189-190. Go to original source... Go to PubMed...
    33. Teh C, McKendrick M. Ciprofloxacin-induced thrombocytopenia. Journal of Infection and Chemotherapy 1993; 27, 213-215. Go to original source... Go to PubMed...
    34. Hasan A., et al. Treatment with rituximab in chronic ITP patients induces long-lasting responses in approximately 30% of patients but even these patients may relapse. Repeated Courses of Rituximab in Chronic ITP: Three Different Regimens. American Journal of Hematology 2009; 84, 661-665. Go to original source... Go to PubMed...
    35. Cooper N., et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. British Journal of Haematology 2004; 125, 232-239. Go to original source... Go to PubMed...

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.